ArticleOncogene2016
Identification of therapeutic targets for glioblastoma by network analysis.
Article in Oncogene, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 21 citations in OpenAlex.
- Systematic Review of Molecular Targeted Therapies for Adult-Type Diffuse Glioma: An Analysis of Clinical and Laboratory Studies.International journal of molecular sciences · 2023Pooled it
- Osteopontin in the Central Nervous System: Roles in Development, Injury, Neurodegeneration, and Neuro-Oncology.Biomolecules · 2026Review
- Glioblastoma-associated macrophages in glioblastoma: from their function and mechanism to therapeutic advances.Cancer gene therapy · 2025Review
- Characteristics of quiescent adult neural stem cells induced by the bFGF/BMP4 combination or BMP4 aloneFrontiers in cellular neuroscience · 2024Article
- Article
- Comparative epigenetic analysis of tumour initiating cells and syngeneic EPSC-derived neural stem cells in glioblastoma.Nature communications · 2021Article
- P32-specific CAR T cells with dual antitumor and antiangiogenic therapeutic potential in gliomas.Nature communications · 2021Article
- Establishment of an Immune-Related Gene Signature for Risk Stratification for Patients with Glioma.Computational and mathematical methods in medicine · 2021Article
- Article
- Heterogeneity Matters: Different Regions of Glioblastoma Are Characterized by Distinctive Tumor-Supporting Pathways.Cancers · 2020Article
- Connecting signaling and metabolic pathways in EGF receptor-mediated oncogenesis of glioblastoma.PLoS computational biology · 2019Article
- Glycosylation Changes in Brain Cancer.ACS chemical neuroscience · 2018Review
- The Retina of Osteopontin deficient Mice in Aging.Molecular neurobiology · 2018Article
- Human osteopontin: Potential clinical applications in cancer (Review).International journal of molecular medicine · 2017Review
- New role of osteopontin in DNA repair and impact on human glioblastoma radiosensitivity.Oncotarget · 2016Article
- Emerging targets for glioblastoma stem cell therapy.Journal of biomedical research · 2016Article
- Targeting NF-κB in glioblastoma: A therapeutic approach.Science advances · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
Abstract
Glioblastoma can originate from terminally differentiated astrocytes and neurons, which can dedifferentiate to a stem cell-like state upon transformation. In this study, we confirmed that transformed dedifferentiated astrocytes and neurons acquired a stem/progenitor cell state, although they still retained gene expression memory from their parental cell. Transcriptional network analysis on these cells identified upregulated genes in three main pathways: Wnt signaling, cell cycle and focal adhesion with the gene Spp1, also known as osteopontin (OPN) serving as a key common node connecting these three pathways. Inhibition of OPN blocked the formation of neurospheres, affected the proliferative capacity of transformed neurons and reduced the expression levels of neural stem cell markers. Specific inhibition of OPN in both murine and human glioma tumors prolonged mice survival. We conclude that OPN is an important player in dedifferentiation of cells during tumor formation, hence its inhibition can be a therapeutic target for glioblastoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.